Report Summary
Cancer immunotherapy, also called biologic therapy, which can predominantly be classed as a form of targeted therapy, It is designed to stimulate the body's immune system to attack tumours.
The global Cancer Immunotherapies market is valued at xx million US$ in 2020 and will reach xx million US$ by the end of 2027, growing at a CAGR of xx% during 2021-2027. The objectives of this study are to define, segment, and project the size of the Cancer Immunotherapies market based on company, product type, end user and key regions.
This report studies the global market size of Cancer Immunotherapies in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Cancer Immunotherapies in these regions.
This research report categorizes the global Cancer Immunotherapies market by top players/brands, region, type and end user. This report also studies the global Cancer Immunotherapies market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Amgen
AstraZeneca
Roche
Bristol-Myers Squibb
Bayer
Merck
ARMO BioSciences (Eli Lilly)
Novartis
Pfizer
Johnson & Johnson
AbbVie
Gilead Sciences
Market size by Product
Monoclonal Antibodies (MABs)
Cancer Vaccines
Immunomodulators
Adoptive Cell transfer
Checkpoint Inhibitors
Market size by End User
Breast Cancer
Leukemia
Lymphoma
Melanoma
Colorectal Cancer
Non-Small Cell Lung Cancer
Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global Cancer Immunotherapies market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2020, and forecast to 2027.
To understand the structure of Cancer Immunotherapies market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Cancer Immunotherapies companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Cancer Immunotherapies submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Cancer Immunotherapies are as follows:
History Year: 2017-2020
Base Year: 2020
Estimated Year: 2020
Forecast Year 2021 to 2027
This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Cancer Immunotherapies market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2020 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table Of Contents
Table of Contents
1 Study Coverage
1.1 Cancer Immunotherapies Product
1.2 Market Segments
1.3 Key Manufacturers Covered
1.4 Market by Type
1.4.1 Global Cancer Immunotherapies Market Size Growth Rate by Product
1.4.2 Monoclonal Antibodies (MABs)
1.4.3 Cancer Vaccines
1.4.4 Immunomodulators
1.4.5 Adoptive Cell transfer
1.4.6 Checkpoint Inhibitors
1.5 Market by End User
1.5.1 Global Cancer Immunotherapies Market Size Growth Rate by End User
1.5.2 Breast Cancer
1.5.3 Leukemia
1.5.4 Lymphoma
1.5.5 Melanoma
1.5.6 Colorectal Cancer
1.5.7 Non-Small Cell Lung Cancer
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Cancer Immunotherapies Market Size
2.1.1 Global Cancer Immunotherapies Revenue 2017-2027
2.1.2 Global Cancer Immunotherapies Sales 2017-2027
2.2 Cancer Immunotherapies Growth Rate by Regions
2.2.1 Global Cancer Immunotherapies Sales by Regions
2.2.2 Global Cancer Immunotherapies Revenue by Regions
3 Breakdown Data by Manufacturers
3.1 Cancer Immunotherapies Sales by Manufacturers
3.1.1 Cancer Immunotherapies Sales by Manufacturers
3.1.2 Cancer Immunotherapies Sales Market Share by Manufacturers
3.1.3 Global Cancer Immunotherapies Market Concentration Ratio (CR5 and HHI)
3.2 Cancer Immunotherapies Revenue by Manufacturers
3.2.1 Cancer Immunotherapies Revenue by Manufacturers (2017-2020)
3.2.2 Cancer Immunotherapies Revenue Share by Manufacturers (2017-2020)
3.3 Cancer Immunotherapies Price by Manufacturers
3.4 Cancer Immunotherapies Manufacturing Base Distribution, Product Types
3.4.1 Cancer Immunotherapies Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Cancer Immunotherapies Product Type
3.4.3 Date of International Manufacturers Enter into Cancer Immunotherapies Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Product
4.1 Global Cancer Immunotherapies Sales by Product
4.2 Global Cancer Immunotherapies Revenue by Product
4.3 Cancer Immunotherapies Price by Product
5 Breakdown Data by End User
5.1 Overview
5.2 Global Cancer Immunotherapies Breakdown Data by End User
6 North America
6.1 North America Cancer Immunotherapies by Countries
6.1.1 North America Cancer Immunotherapies Sales by Countries
6.1.2 North America Cancer Immunotherapies Revenue by Countries
6.1.3 United States
6.1.4 Canada
6.1.5 Mexico
6.2 North America Cancer Immunotherapies by Product
6.3 North America Cancer Immunotherapies by End User
7 Europe
7.1 Europe Cancer Immunotherapies by Countries
7.1.1 Europe Cancer Immunotherapies Sales by Countries
7.1.2 Europe Cancer Immunotherapies Revenue by Countries
7.1.3 Germany
7.1.4 France
7.1.5 UK
7.1.6 Italy
7.1.7 Russia
7.2 Europe Cancer Immunotherapies by Product
7.3 Europe Cancer Immunotherapies by End User
8 Asia Pacific
8.1 Asia Pacific Cancer Immunotherapies by Countries
8.1.1 Asia Pacific Cancer Immunotherapies Sales by Countries
8.1.2 Asia Pacific Cancer Immunotherapies Revenue by Countries
8.1.3 China
8.1.4 Japan
8.1.5 Korea
8.1.6 India
8.1.7 Australia
8.1.8 Indonesia
8.1.9 Malaysia
8.1.10 Philippines
8.1.11 Thailand
8.1.12 Vietnam
8.1.13 Singapore
8.2 Asia Pacific Cancer Immunotherapies by Product
8.3 Asia Pacific Cancer Immunotherapies by End User
9 Central & South America
9.1 Central & South America Cancer Immunotherapies by Countries
9.1.1 Central & South America Cancer Immunotherapies Sales by Countries
9.1.2 Central & South America Cancer Immunotherapies Revenue by Countries
9.1.3 Brazil
9.2 Central & South America Cancer Immunotherapies by Product
9.3 Central & South America Cancer Immunotherapies by End User
10 Middle East and Africa
10.1 Middle East and Africa Cancer Immunotherapies by Countries
10.1.1 Middle East and Africa Cancer Immunotherapies Sales by Countries
10.1.2 Middle East and Africa Cancer Immunotherapies Revenue by Countries
10.1.3 GCC Countries
10.1.4 Turkey
10.1.5 Egypt
10.1.6 South Africa
10.2 Middle East and Africa Cancer Immunotherapies by Product
10.3 Middle East and Africa Cancer Immunotherapies by End User
11 Company Profiles
11.1 Amgen
11.1.1 Amgen Company Details
11.1.2 Company Business Overview
11.1.3 Amgen Cancer Immunotherapies Sales, Revenue and Gross Margin (2017-2020)
11.1.4 Amgen Cancer Immunotherapies Products Offered
11.1.5 Amgen Recent Development
11.2 AstraZeneca
11.2.1 AstraZeneca Company Details
11.2.2 Company Business Overview
11.2.3 AstraZeneca Cancer Immunotherapies Sales, Revenue and Gross Margin (2017-2020)
11.2.4 AstraZeneca Cancer Immunotherapies Products Offered
11.2.5 AstraZeneca Recent Development
11.3 Roche
11.3.1 Roche Company Details
11.3.2 Company Business Overview
11.3.3 Roche Cancer Immunotherapies Sales, Revenue and Gross Margin (2017-2020)
11.3.4 Roche Cancer Immunotherapies Products Offered
11.3.5 Roche Recent Development
11.4 Bristol-Myers Squibb
11.4.1 Bristol-Myers Squibb Company Details
11.4.2 Company Business Overview
11.4.3 Bristol-Myers Squibb Cancer Immunotherapies Sales, Revenue and Gross Margin (2017-2020)
11.4.4 Bristol-Myers Squibb Cancer Immunotherapies Products Offered
11.4.5 Bristol-Myers Squibb Recent Development
11.5 Bayer
11.5.1 Bayer Company Details
11.5.2 Company Business Overview
11.5.3 Bayer Cancer Immunotherapies Sales, Revenue and Gross Margin (2017-2020)
11.5.4 Bayer Cancer Immunotherapies Products Offered
11.5.5 Bayer Recent Development
11.6 Merck
11.6.1 Merck Company Details
11.6.2 Company Business Overview
11.6.3 Merck Cancer Immunotherapies Sales, Revenue and Gross Margin (2017-2020)
11.6.4 Merck Cancer Immunotherapies Products Offered
11.6.5 Merck Recent Development
11.7 ARMO BioSciences (Eli Lilly)
11.7.1 ARMO BioSciences (Eli Lilly) Company Details
11.7.2 Company Business Overview
11.7.3 ARMO BioSciences (Eli Lilly) Cancer Immunotherapies Sales, Revenue and Gross Margin (2017-2020)
11.7.4 ARMO BioSciences (Eli Lilly) Cancer Immunotherapies Products Offered
11.7.5 ARMO BioSciences (Eli Lilly) Recent Development
11.8 Novartis
11.8.1 Novartis Company Details
11.8.2 Company Business Overview
11.8.3 Novartis Cancer Immunotherapies Sales, Revenue and Gross Margin (2017-2020)
11.8.4 Novartis Cancer Immunotherapies Products Offered
11.8.5 Novartis Recent Development
11.9 Pfizer
11.9.1 Pfizer Company Details
11.9.2 Company Business Overview
11.9.3 Pfizer Cancer Immunotherapies Sales, Revenue and Gross Margin (2017-2020)
11.9.4 Pfizer Cancer Immunotherapies Products Offered
11.9.5 Pfizer Recent Development
11.10 Johnson & Johnson
11.10.1 Johnson & Johnson Company Details
11.10.2 Company Business Overview
11.10.3 Johnson & Johnson Cancer Immunotherapies Sales, Revenue and Gross Margin (2017-2020)
11.10.4 Johnson & Johnson Cancer Immunotherapies Products Offered
11.10.5 Johnson & Johnson Recent Development
11.11 AbbVie
11.12 Gilead Sciences
12 Future Forecast
12.1 Cancer Immunotherapies Market Forecast by Regions
12.1.1 Global Cancer Immunotherapies Sales Forecast by Regions 2021-2027
12.1.2 Global Cancer Immunotherapies Revenue Forecast by Regions 2021-2027
12.2 Cancer Immunotherapies Market Forecast by Product
12.2.1 Global Cancer Immunotherapies Sales Forecast by Product 2021-2027
12.2.2 Global Cancer Immunotherapies Revenue Forecast by Product 2021-2027
12.3 Cancer Immunotherapies Market Forecast by End User
12.4 North America Cancer Immunotherapies Forecast
12.5 Europe Cancer Immunotherapies Forecast
12.6 Asia Pacific Cancer Immunotherapies Forecast
12.7 Central & South America Cancer Immunotherapies Forecast
12.8 Middle East and Africa Cancer Immunotherapies Forecast
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Macroscopic Indicators
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Cancer Immunotherapies Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
